CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-02 | Beneski Benjamin Machinas SVP, Chief Technical Officer | Grant or award · Restricted Stock Unit | +105,720 | 105,720 | ||
| 2026-02-02 | Chang David D President and CEO | Sale | −95,269 | $1.80 | $171K | 5,185,862 |
| 2026-02-02 | Chang David D President and CEO | Grant or award · Stock Option (Right to buy) | +1,387,931 | 1,387,931 | ||
| 2026-02-02 | Chang David D President and CEO | Grant or award · Restricted Stock Unit | +392,586 | 392,586 | ||
| 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Sale | −24,001 | $1.76 | $42K | 1,252,795 |
| 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to buy) | +539,072 | 539,072 | ||
| 2026-02-02 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award · Restricted Stock Unit | +152,480 | 152,480 | ||
| 2026-02-02 | Yoshiyama Annie SVP, Finance | Sale | −4,167 | $1.72 | $7K | 130,322 |
| 2026-02-02 | Yoshiyama Annie SVP, Finance | Grant or award · Stock Option (Right to buy) | +179,691 | 179,691 | ||
| 2026-02-02 | Yoshiyama Annie SVP, Finance | Grant or award · Restricted Stock Unit | +50,827 | 50,827 | ||
| 2026-02-02 | Roberts Zachary EVP of R&D | Sale | −35,700 | $1.77 | $63K | 581,166 |
| 2026-02-02 | Roberts Zachary EVP of R&D | Grant or award · Stock Option (Right to buy) | +718,763 | 718,763 | ||
| 2026-02-02 | Roberts Zachary EVP of R&D | Grant or award · Restricted Stock Unit | +203,307 | 203,307 | ||
| 2026-02-02 | Douglas Earl Martin SVP, General Counsel | Sale | −22,900 | $1.76 | $40K | 564,948 |
| 2026-02-02 | Douglas Earl Martin SVP, General Counsel | Grant or award · Stock Option (Right to buy) | +539,072 | 539,072 | ||
| 2026-02-02 | Douglas Earl Martin SVP, General Counsel | Grant or award · Restricted Stock Unit | +152,480 | 152,480 | ||
| 2026-02-02 | Belldegrun Arie Director | Grant or award · Stock Option (Right to buy) | +929,913 | 929,913 | ||
| 2026-02-02 | Belldegrun Arie Director | Grant or award · Restricted Stock Unit | +263,033 | 263,033 | ||
| 2026-01-21 | Roberts Zachary EVP of R&D | Sale | −26,269 | $1.56 | $41K | 616,866 |
| 2025-12-18 | Kazam Joshua A Director | Option exercise | +47,700 | 350,763 |
Page 2 of 18 · 348 trades